Overview

PMT for Severe-CDI

Status:
Recruiting

Trial end date:
2022-07-01

Target enrollment:

Participant gender:

Summary

This is a randomized, open label, comparative, Phase II study to determine whether fecal microbiota transplant using Penn Microbiome Therapy products helps standard therapy to treat severe Clostridium difficile infection (C diff).

Phase:

Phase 2

Details

Lead Sponsor:

University of Pennsylvania

Treatments:

Anti-Bacterial Agents
Antibiotics, Antitubercular